Last reviewed · How we verify
GnRH Agonist (Lupron Depot)
Lupron Depot is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.
Lupron Depot is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. Used for Central precocious puberty, Prostate cancer (advanced), Endometriosis.
At a glance
| Generic name | GnRH Agonist (Lupron Depot) |
|---|---|
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology; Oncology; Urology |
| Phase | Phase 3 |
Mechanism of action
GnRH agonists work by initially stimulating the pituitary gland's GnRH receptors, causing a brief surge in LH and FSH. With continuous exposure, this leads to receptor desensitization and downregulation, resulting in sustained suppression of gonadotropins and consequent reduction in testosterone (in males) or estrogen (in females). This hormonal suppression is therapeutically exploited in conditions where sex hormone reduction is beneficial.
Approved indications
- Central precocious puberty
- Prostate cancer (advanced)
- Endometriosis
- Uterine fibroids
Common side effects
- Hot flashes
- Injection site reaction
- Headache
- Mood changes/depression
- Decreased libido
- Erectile dysfunction
- Bone density loss
Key clinical trials
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (PHASE1)
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery (PHASE2)
- Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (PHASE2)
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: